wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39169789-043C44AA-B8EB-4CF2-AEBC-8DE7EB617FBA
Q39169789-043C44AA-B8EB-4CF2-AEBC-8DE7EB617FBA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39169789-043C44AA-B8EB-4CF2-AEBC-8DE7EB617FBA
Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.
P2860
Q39169789-043C44AA-B8EB-4CF2-AEBC-8DE7EB617FBA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39169789-043C44AA-B8EB-4CF2-AEBC-8DE7EB617FBA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8e01db904ee02738bfc3c1b2aea9c601c65d8a29
P2860
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).